Netherlands· NL-f14aa35d15d8
Fibclot 1,5 g, poeder en oplosmiddel voor oplossing voor injectie/infusie
A fibrinogen, human product containing fibrinogeen, humaan, registered in Netherlands by Laboratoire Francais Du Fractionnement Et Des Biotechnologies. The same ATC class is registered in 11 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Fibrinogen, human is registered in 11 of 19 countries.
Countries holding a registration under ATC B02BB01 (fibrinogen, human), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 7 of them publish a price we can compare per daily dose
Fibrinogen, human · ATC B02BB01
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
Price per daily dose
What a daily dose of fibrinogen, human costs, country by country.
Normalised to the WHO defined daily dose (5 g), the median price runs from $2.30 in Czechia to $2694.05 in Switzerland — a ×1171 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Fibrinogen, human · price per daily dose (5 g)
USD · FX 28 Sept 2026
- CH Switzerland$2694.05
- CZ Czechia$2.30
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- FIBRINOGEEN, HUMAAN
- Manufacturer
- Laboratoire Francais Du Fractionnement Et Des Biotechnologies
- Country
- Netherlands (NL)
- ATC code
- B02BB01
- ATC class
- Fibrinogen, human
- Defined daily dose
- 5 g, P
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_id116873
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
2 interactions on record for fibrinogen, human.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Fibrinogen, human · interactions on record
2 records
- 2 severe
Most severe, free to view
- CarfilzomibL01XG02severe
- CarfilzomibL01XX45severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Fibrinogen, human in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomARTISS solution for sealant 10ml pre-filled syringesBaxter Healthcare Ltd
- BelgiumArtissBaxter
- IrelandFIBRYGA 2 g powder and solvent for solution for injection/infusionOctapharma (IP)
- SpainFIBCLOT 1,5 G POLVO Y DISOLVENTE PARA SOLUCION INYECTABLE Y PARA PERFUSIONLaboratoire Francais Du Fractionnement Et Des Biotechnologies
- GermanyFibclotLaboratoire Francais Du Fractionnement Et Des Biotechnologies
- SwedenFibclot 1,5 g Pulver och vätska till injektions-/infusionsvätska, lösningLaboratoire français du Fractionnement et des Biotechnologies
- FinlandFibclotLaboratoire Francais du Fractionnement et des Biotechnologies
- CzechiaFIBRYGAOctapharma (IP) SPRL, Anderlecht
Authorised across Europe · EMA
The same active substance is authorised in 29 EEA countries. Names it is sold under:
- Austria · Fibclot, Fibryga
- Belgium · Fibclot, Fibryga
- Bulgaria · Fibryga, Хемокомплетан P
- Cyprus · Fibryga, Riastap
- Czechia · Fibryga, Haemocomplettan P
- Germany · Fibclot, Fibryga
- Denmark · Fibclot, Fibryga
- Estonia · Fibryga
- Spain · Fibclot, Fibryga
- Finland · Fibclot, Fibryga
- France · Clottafact, Fibryga
- United Kingdom (Northern Ireland) · Fibclot, Fibryga
- Greece · Fibclot, Riastap
- Croatia · Fibryga
- Hungary · Fibclot, Fibryga
- Ireland · Fibryga, Riastap
- Iceland · Fibryga, Riastap
- Italy · Fibriclotte, Fibryga
- Lithuania · Fibryga
- Luxembourg · Fibclot, Fibryga
- Latvia · Fibryga
- Malta · Fibryga, Riastap
- Norway · Fibclot, Fibryga
- Poland · Fibryga, Riastap
- Portugal · Fibryga, Haemocomplettan
- Romania · Fibryga, Haemocomplettan P
- Sweden · Fibclot, Fibryga
- Slovenia · Fibrema, Prufibry
- Slovakia · Fibryga, Riastap
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bd9abf44-041a-447e-8e84-da2783fca11e GET /v1/drugs/bd9abf44-041a-447e-8e84-da2783fca11e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Poeder en oplosmiddel voor oplossing voor injectie, Poeder en oplosmiddel voor oplossing voor infusie",
"route": "Intraveneus gebruik",
"soort": "RVG",
"source": "cbg_meb",
"smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h116873_smpc.pdf",
"strength": null,
"atc_label": "Human Fibrinogen",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg116873",
"excipients": [
"ARGININEHYDROCHLORIDE, (L-)",
"GLYCINE (E 640)",
"ISOLEUCINE, (L-)",
"LYSINEHYDROCHLORIDE, L-",
"STIKSTOF (HEAD SPACE) (E 941)",
"TRINATRIUMCITRAAT 2-WATER (E 331)",
"WATER VOOR INJECTIE"
],
"substances": [
"FIBRINOGEEN, HUMAAN"
],
"leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h116873.pdf",
"authorised_at": "2016/02/22",
"procedure_number": "DE/H/1946/001",
"dispensing_status": "Uitsluitend recept",
"registration_number": "116873",
"additional_monitoring": "N"
}See everything about fibrinogen, human.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.